EGT022 (human Derived Recombinant Polypeptide)
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
EG-Decorin accelerates wound healing through a reduction of edema, maturation and stabilization of impaired vessels, and enhanced replacement of granulation tissues on ischemic wounds. EGT022 may have potential benefits for other ischemic disorders such a
Send an Inquiry
RE:
Participants
You

- EG-Decorin (compound name: EGT022), a topical ointment for pressure sore and diabetic foot ulcer, induces rapid repair of damaged capillaries. Thus, it promotes enhanced wound healing. EG-Decorin is majorly composed of human-derived protein ADAM-15 and repairs capillaries via recruiting pericytes.

- In the molecular aspect, EGT022 is a RGD motif containing recombinant polypeptide from human derived protein ADAM-15. EGT022 has a molecular weight of 6.1- kDa and is composed of over 58 amino acids.

- EGT022 is a therapeutic agent for chronic ischemic disorders such as pressure sore, diabetic foot ulcer.

- EG-Decorin (EGT022) is first in class with the new RGD motif mechanism.
- EG-Decorin accelerates wound healing through a reduction of edema, maturation and stabilization of impaired vessels, and enhanced replacement of granulation tissues on ischemic wounds.
- No significant toxicity was observed in pre-clinical toxicology studies.
- EGT022 may have potential benefits for other ischemic disorders such as diabetic retinopathy.

- EG-Decorin induces accelerated wound closure and replacement of granulation tissue in pressure sore induced in normal, diabetic, steroid treated, and old aged mice models.
- EG-Decorin improves proliferative activities of epidermal cells in rabbit full-thickness ear wound model.
- EG-Decorin does not induce skin contraction on the wound lesion during wound healing.
- EG-Decorin improves micro-vascular disorders caused by ischemia-reperfusion cycles.
- EG-Decorin promotes stabilization and maturation of impaired vessels in wounded lesions.
- Expression system in Pichia pastoris and 250L production and purification process has been established.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
- Out licensing
- Collaboration
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
GOVERNMENT INSTITUTE

Opportunity Contact